Although adropin was found to be a potential regulator of CV functions, playing a key protective role in the pathogenesis of HF and T2DM [60], there is a limiting number of preclinical data and clinical evidence corresponding to our hypothesis. This evidence concerns the gene ENHO and type 2 diabetes mellitus.